Trials / Recruiting
RecruitingNCT07449936
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EYP-1901 | Intravitreal Injection |
| DRUG | Aflibercept (2.0 mg) | Intravitreal Injection |
Timeline
- Start date
- 2026-02-16
- Primary completion
- 2027-10-01
- Completion
- 2028-10-01
- First posted
- 2026-03-04
- Last updated
- 2026-04-07
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07449936. Inclusion in this directory is not an endorsement.